Maralixibat chloride

From Wikipedia, the free encyclopedia

Maralixibat chloride
Maralixibat chloride skeletal.svg
Clinical data
Trade namesLivmarli
Other namesLUM001
License data
Routes of
administration		By mouth
Drug classIleal bile acid transporter (IBAT) inhibitor
ATC code
Legal status
Legal status
Identifiers
  • 1-[4-({4-[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydro-1-benzothiepin-5-yl]phenoxy}methyl)benzyl]-4-aza-1-azoniabicyclo[2.2.2]octane
CAS Number
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC40H56ClN3O4S
Molar mass710.42 g·mol−1
3D model (JSmol)
  • CCCCC1(CCCC)CS(=O)(=O)C2=CC=C(C=C2[C@H]([C@H]1O)C1=CC=C(OCC2=CC=C(C[N+]34CCN(CC3)CC4)C=C2)C=C1)N(C)C
  • InChI=1S/C40H56N3O4S/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3/q+1/t38-,39-/m1/s1
  • Key:STPKWKPURVSAJF-LJEWAXOPSA-N

Maralixibat chloride, sold under the brand name Livmarli, is a medication used to treat cholestatic pruritus in people with Alagille syndrome.[1] Maralixibat chloride is an ileal bile acid transporter (IBAT) inhibitor.[1]

Maralixibat was approved for medical use in the United States in September 2021.[1][2][3]

History[]

Maralixibat was granted orphan drug designations in 2013,[4][5] and in 2020.[6]

Names[]

Maralixibat chloride is the international nonproprietary name (INN).[7]

References[]

  1. ^ a b c d "Livmarli- maralixibat chloride solution". DailyMed. Retrieved 31 October 2021.
  2. ^ "Maralixibat: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 29 September 2021.
  3. ^ "U.S. FDA Approves Livmarli (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older". Mirum Pharmaceuticals (Press release). 29 September 2021. Retrieved 29 September 2021 – via Business Wire.
  4. ^ "Maralixibat Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 4 September 2013. Retrieved 29 September 2021.
  5. ^ "Maralixibat Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 4 September 2013. Retrieved 29 September 2021.
  6. ^ "Maralixibat Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 21 October 2020. Retrieved 29 September 2021.
  7. ^ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.

External links[]

  • "Maralixibat". Drug Information Portal. U.S. National Library of Medicine.
  • "Maralixibat chloride". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02160782 for "Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) (ICONIC)" at ClinicalTrials.gov


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""